Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

Pharmaceutical Research

Volumn 28, Issue 5, 2011, Pages 949-961

  Kumar, Sandeep ^a   Singh, Satish K ^a   Wang, Xiaoling ^a   Rup, Bonita ^a   Gill, Davinder ^a  

^a PFIZER INC   (United States)

Author keywords

aggregation; biotherapeutics; cross motif; drug development; immunogenicity

Indexed keywords

ABCIXIMAB; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; DACLIZUMAB; DRUG ANTIBODY; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OKT 3; PANITUMUMAB;

AGGREGATION PRONE REGION; AMINO ACID SEQUENCE; B LYMPHOCYTE; BIOLOGICAL THERAPY; DRUG DESIGN; DRUG STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN STRUCTURE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DATABASE; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEINS;

EID: 79955610019     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0414-9     Document Type: Review

References (50)

1. TJ Giezen AK Mantel-Teeuwisse SMJM Straus H Schellekens HGM Leufkens ACG Egberts 2008 Safety-related regulatory actions for biologicals approved in the United States and the European Union JAMA. 300 16 1887 1896 18940975 10.1001/jama.300.16.1887 1:CAS:528:DC%2BD1cXht12iur%2FN
2. AS Rosenberg 2006 Effects of protein aggregates: an immunologic perspective AAPS J. 8 3 E501 E507 17025268 10.1208/aapsj080359 (Pubitemid 44294011)
3. JF Carpenter TW Randolph W Jiskoot DJ Crommelin CR Middaugh G Winter, et al. 2009 Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality J Pharm Sci. 98 4 1201 1205 18704929 10.1002/jps.21530 1:CAS:528:DC%2BD1MXktlSisLs%3D
4. SK Singh 2011 Impact of product-related factors on immunogenicity of biotherapeutics J Pharm Sci 100 2 354 387 20740683 10.1002/jps.22276 1:CAS:528:DC%2BC3cXhs1ags7bL
5. M Sauerborn V Brinks W Jiskoot H Schellekens 2010 Immunological mechanism underlying the immune response to recombinant human protein therapeutics Trends Pharmacol Sci. 31 2 53 59 19963283 10.1016/j.tips.2009.11.001 1:CAS:528:DC%2BC3cXhtlejsbo%3D
6. CX Moss SP Matthews DJ Lamont C Watts 2005 Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules J Biol Chem. 280 18 18498 18503 15749706 10.1074/jbc.M501241200 1:CAS:528:DC%2BD2MXjsl2htbs%3D (Pubitemid 41389099)
7. McNally EJ, Hastedt JE, editors. Protein formulation and delivery. New York: Informa Healthcare; 2008.
8. Laurence JS, Middaugh RC. Fundamental structures and behaviors of proteins. In: Wang W, Roberts CJ, editors. Aggregation of therapeutic proteins. Hoboken: Wiley; 2010. p. 1-61.
9. JD Schmit K Ghosh K Dill 2011 What drives amyloid molecules to assemble into oligomers and fibrils? Biophys J. 100 2 450 458 21244841 10.1016/j.bpj.2010.11.041 1:CAS:528:DC%2BC3MXmsVGmtg%3D%3D
10. M Clark 2000 Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today. 21 8 397 402 10916143 10.1016/S0167-5699(00)01680-7 1:CAS:528:DC%2BD3cXlsVOqsLo%3D (Pubitemid 30612301)
11. LG Presta 2006 Engineering of therapeutic antibodies to minimize immunogenicity and optimize function Adv Drug Deliv Rev. 58 5-6 640 656 16904789 10.1016/j.addr.2006.01.026 1:CAS:528:DC%2BD28XoslKrsLY%3D (Pubitemid 44262411)
12. F Harding MM Stickler J Razo R DuBridge 2010 The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions mAbs 2 3 1 10 10.4161/mabs.2.3.11641
13. A Beck JM Reichert T Wurch 2010 5th European antibody congress 2009: November 30-December 2, 2009, Geneva Switzerland. mAbs. 2 2 108 128 10.4161/mabs.2.2.11302
14. Kumar S, Singh SK, Gromiha MM. Temperature dependent molecular adaptations, microbial proteins. In: Flickinger MC,Drew SW, Spier RE editors. Encyclopedia of Industrial Biotechnology. John Wiley & Sons; 2010. p. 4647-4661.
15. S Hermeling H Schellekens C Maas MF Gebbink DJ Crommelin W Jiskoot 2006 Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation J Pharm Sci. 95 5 1084 1096 16552750 10.1002/jps.20599 1:CAS:528:DC%2BD28Xkslejur8%3D (Pubitemid 43723167)
16. AH Fradkin JF Carpenter TW Randolph 2009 Immunogenicity of aggregates of recombinant human growth hormone in mouse models J Pharm Sci 98 9 3247 3264 19569057 10.1002/jps.21834 1:CAS:528:DC%2BD1MXptl2itL0%3D
17. R Foulkes 2002 Preclinical safety evaluation of monoclonal antibodies Toxicology. 174 1 21 26 11972988 10.1016/S0300-483X(02)00053-7 1:CAS:528:DC%2BD38XjtVShtLk%3D (Pubitemid 34327823)
18. S Pechmann ED Levy GG Tartaglia M Vendruscolo 2009 Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins Proc Natl Acad Sci U S A. 106 25 10159 10164 19502422 10.1073/pnas.0812414106 1:CAS:528:DC%2BD1MXot1Gktb8%3D
19. JA Siepen SE Radford DR Westhead 2003 β Edge strands in protein structure prediction and aggregation Protein Sci. 12 10 2348 2359 14500893 10.1110/ps.03234503 1:CAS:528:DC%2BD3sXnslKlsLY%3D (Pubitemid 37163369)
20. R Nelson D Eisenberg 2006 Recent atomic models of amyloid fibril structure Curr Opin Struct Biol. 16 2 260 265 16563741 10.1016/j.sbi.2006.03.007 1:CAS:528:DC%2BD28Xjs1Grsbk%3D
21. R Nelson MR Sawaya M Balbirnie AO Madsen C Riekel R Grothe, et al. 2005 Structure of the cross-b spine of amyloid-like fibrils Nature. 435 7043 773 778 15944695 10.1038/nature03680 1:CAS:528:DC%2BD2MXkvVGgsLY%3D (Pubitemid 40839722)
22. MR Sawaya S Sambashivan R Nelson MI Ivanova SA Sievers MI Apostol, et al. 2007 Atomic structures of amyloid cross-b spines reveal varied steric zippers Nature. 447 7143 453 457 17468747 10.1038/nature05695 1:CAS:528: DC%2BD2sXlsFOhu7o%3D (Pubitemid 46816731)
23. S Maurer-Stroh M Debulpaep N Kuemmerer ML de la Paz IC Martins J Reumers, et al. 2010 Exploring the sequence determinants of amyloid structure using position-specific scoring matrices Nat Methods. 7 3 237 242 20154676 10.1038/nmeth.1432 1:CAS:528:DC%2BC3cXhvFGmsbw%3D
24. L Wang SK Maji MR Sawaya D Eisenberg R Riek 2008 Bacterial inclusion bodies contain amyloid-like structure PLoS Biol. 6 8 1791 1801 10.1371/journal.pbio.0060195 1:CAS:528:DC%2BD1cXhtV2rtbfP
25. Kumar S, Wang X, Singh SK. Identification and impact of aggregation prone regions in proteins and therapeutic mAbs. In: Wang W, Roberts CJ, editors. Aggregation of therapeutic proteins. Hoboken: Wiley; 2010. p. 103-18.
26. C Maas S Hermeling B Bouma W Jiskoot MFBG Gebbink 2007 A role for protein misfolding in immunogenicity of biopharmaceuticals J Biol Chem. 282 4 2229 2236 17135263 10.1074/jbc.M605984200 1:CAS:528:DC%2BD2sXmsVaqug%3D%3D (Pubitemid 47076754)
27. Brummitt RK, Nesta DP, Chang L, Chase SF, Laue TM, Roberts CJ. Nonnative aggregation of an IgG1 antibody in acidic conditions: Part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. J Pharm Sci. 2011; In press.
28. N Chennamsetty V Voynov V Kayser B Helk BL Trout 2009 Design of therapeutic proteins with enhanced stability Proc Natl Acad Sci U S A. 106 29 11937 11942 19571001 10.1073/pnas.0904191106 1:CAS:528:DC%2BD1MXpsF2ks70%3D
29. N Chennamsetty B Helk V Voynov V Kayser BL Trout 2009 Aggregation-prone motifs in human immunoglobulin G J Mol Biol. 391 2 404 413 19527731 10.1016/j.jmb.2009.06.028 1:CAS:528:DC%2BD1MXptVeisLY%3D
30. X Wang TK Das SK Singh S Kumar 2009 Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies mAbs 1 3 1 14 10.4161/mabs.1.3.8035
31. X Wang S Singh S Kumar 2010 Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis Pharm Res. 27 8 1512 1529 20422267 10.1007/s11095-010-0143-5 1:CAS:528:DC%2BC3cXlt1amsLk%3D
32. AS De Groot J McMurry L Moise 2008 Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates Curr Opin Pharmacol. 8 5 620 626 18775515 10.1016/j.coph.2008.08.002
33. AS De Groot L Moise 2007 Prediction of immunogenicity for therapeutic proteins: state of the art Curr Opin Drug Discov Devel. 10 3 332 340 17554860 (Pubitemid 46800227)
34. JA Greenbaum PH Andersen M Blythe H-H Bui RE Cachau J Crowe, et al. 2007 Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools J Mol Recognit. 20 2 75 82 17205610 10.1002/jmr.815 1:CAS:528:DC%2BD2sXltF2ns7o%3D (Pubitemid 46761248)
35. R Vita L Zarebski JA Greenbaum H Emami I Hoof N Salimi, et al. 2010 The immune epitope database 2.0 Nucleic Acids Res 38 Database issue D854 862 19906713 10.1093/nar/gkp1004 1:CAS:528:DC%2BC3cXktl2isg%3D%3D
36. CJ Bryson TD Jones MP Baker 2010 Prediction of immunogenicity of therapeutic proteins: validity of computational tools BioDrugs. 24 1 1 8 20055528 10.2165/11318560-000000000-00000 1:CAS:528:DC%2BC3cXislSrtrw%3D
37. AJ Godkin KJ Smith A Willis MV Tejada-Simon J Zhang T Elliott, et al. 2001 Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions J Immunol. 166 11 6720 6727 11359828 1:CAS:528:DC%2BD3MXjvFarurY%3D (Pubitemid 32467215)
38. Gebbink MF, Bouma B. In: Office USPT, editor. Method for detecting and/or removing protein comprising a cross-beta structure from a pharmaceutical composition. USA: UMC Utrecht Holding B.V; 2007.
39. Filipe V, Hawe A, Schellekens H, Jiskoot W. Aggregation and Immunogenictiy of Therapeutic Proteins. In: Wang W, Roberts CJ, editors. Aggregation of therapeutic proteins. Hoboken: Wiley; 2010. p. 403-33.
40. A Basu K Yang M Wang S Liu R Chintala T Palm, et al. 2006 Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation Bioconjug Chem. 17 3 618 630 16704199 10.1021/bc050322y 1:CAS:528:DC%2BD28XktVSktrc%3D (Pubitemid 43794371)
41. MDFS Barbosa J Vielmetter S Chu DD Smith J Jacinto 2006 Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity Clin Immunol. 118 1 42 50 16260183 10.1016/j.clim.2005.08.017 1:CAS:528:DC%2BD2MXhtlGlsr7K (Pubitemid 43012045)
42. A-M Fernandez-Escamilla F Rousseau J Schymkowitz L Serrano 2004 Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat Biotechnol. 22 10 1302 1306 15361882 10.1038/nbt1012 1:CAS:528:DC%2BD2cXotFGqtb8%3D (Pubitemid 39336784)
43. GG Tartaglia A Cavalli R Pellarin A Caflisch 2005 Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences Protein Sci. 14 10 2723 2734 16195556 10.1110/ps.051471205 1:CAS:528:DC%2BD2MXhtVOrurzJ (Pubitemid 41395598)
44. M Karpusas M Nolte CB Benton W Meier WN Lipscomb S Goelz 1997 The crystal structure of human interferon beta at 2.2-A resolution Proc Natl Acad Sci U S A. 94 22 11813 11818 9342320 10.1073/pnas.94.22.11813 1:CAS:528: DyaK2sXntFSnu7k%3D (Pubitemid 27467800)
45. S Lacroix-Desmazes A-M Navarrete S Andre J Bayry SV Kaveri S Dasgupta 2008 Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A Blood. 112 2 240 249 18469198 10.1182/blood-2008-02-124941 1:CAS:528:DC%2BD1cXos1Cisbc%3D
46. TD Jones WJ Phillips BJ Smith CA Bamford PD Nayee TP Baglin, et al. 2005 Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII J Thromb Haemost. 3 5 991 1000 15869596 10.1111/j.1538-7836.2005.01309.x 1:CAS:528:DC%2BD2MXltlOitbo%3D (Pubitemid 41632831)
47. AS De Groot L Moise JA McMurry E Wambre L Van Overtvelt P Moingeon, et al. 2008 Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes" Blood. 112 8 3303 3311 18660382 10.1182/blood-2008-02- 138073
48. J Richard N Prang 2010 The formulation and immunogenicity of therapeutic proteins: product quality as a key factor IDrugs. 13 8 550 558 20721826 1:CAS:528:DC%2BC3cXhtlGjurbO
49. AS Kolaskar PC Tongaonkar 1990 A semi-empirical method for prediction of antigenic determinants on protein antigens FEBS Lett. 276 1-2 172 174 1702393 10.1016/0014-5793(90)80535-Q 1:CAS:528:DyaK3MXktVGntw%3D%3D
50. T Lührs C Ritter M Adrian D Riek-Loher B Bohrmann H Döbeli, et al. 2005 3D structure of Alzheimer's amyloid-b(1-42) fibrils Proc Natl Acad Sci U S A. 102 48 17342 17347 16293696 10.1073/pnas.0506723102 (Pubitemid 41740868)